Strs Ohio Reduces Position in Pfizer Inc. $PFE

Strs Ohio lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,044,347 shares of the biopharmaceutical company’s stock after selling 129,035 shares during the quarter. Strs Ohio’s holdings in Pfizer were worth $57,405,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of PFE. Kepler Cheuvreux Suisse SA bought a new stake in Pfizer during the 3rd quarter worth approximately $16,613,000. Mackenzie Financial Corp boosted its holdings in Pfizer by 119.6% in the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock valued at $79,157,000 after purchasing an additional 1,691,773 shares during the period. Penn Davis Mcfarland Inc. boosted its holdings in Pfizer by 50.9% in the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after purchasing an additional 57,777 shares during the period. Ameriprise Financial Inc. grew its position in shares of Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. Finally, Danske Bank A S bought a new position in shares of Pfizer in the third quarter worth $81,298,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $24.29 on Friday. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a market cap of $138.45 billion, a P/E ratio of 18.54 and a beta of 0.35. The firm’s fifty day moving average price is $25.68 and its 200-day moving average price is $26.24.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period in the previous year, the business earned $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PFE shares. CICC Research started coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective on the stock. Wolfe Research restated an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a report on Tuesday, June 23rd. Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. Finally, Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, June 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.